Calidi Biotherapeutics 주식 (AMEX: CLDI)

에 대한 최신 뉴스 Calidi Biotherapeutics (AMEX:CLDI) 주식

Calidi Biotherapeutics

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent.

Earnings

Earnings Beats

News

BNTC

Benitec Biopharma Q1 2025 GAAP EPS $(0.48) Beats $(0.55) Estimate

WIIM

MLSS

Milestone Scientific shares are trading higher after the company reported better-than-expected Q3 financials.

Hedge Funds

General

MRCY

Starboard Value's Q3 2024 13F Filing Reveals Complete Exits From Mercury Systems With 2.29M Shares, AECOM With 625K Shares

BENF

Beneficient shares are trading higher after the company reported a year-over-year increase in Q2 revenue results.

OPTX

Syntec Optics Holdings Q3 EPS $0.00 Down From $0.01 YoY, Sales $7.86M Up From $6.6M YoY

Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest <a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957424006690/xslForm13F_X02/infotable.xml">Form 13F</a> on Thursday and disclosed its trading activity from the prior quarter. Here's a look at Tiger Global's <a href="https://www.benzinga.com/opinion/24/08/40422936/steal-these-two-stock-ideas-from-the-best-investors-in-the-world">portfolio changes.&nbsp;</a>
The Details: Tiger Global has $23.439 billion in assets under management and made no changes to its top five holdings:&nbsp;
<ul>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) </li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) </li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
New Positions: Tiger Global opened three new positions including a $801.3 million stake in Flutter Entertainment Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), the parent company of FanDuel. The fund also opened a $201.4 million position in Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) and a $48.9 million position in South Korean e-commerce platform Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>). 
Notable Trades: Tiger Global added 564,090 shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to its portfolio, bringing its total number of shares owned to 3,634,980. The fund also increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) by 195,714 shares, bringing its current holdings to 5,839,256 shares valued at $897.5 million. 
Closed Positions: The hedge fund closed out its positions in Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) and DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image created using artificial intelligence via MidJourney.

Movers

ALAB

CPNG

DXCM

FLUT

GOOGL

MSFT

TTWO

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

RVYL

Ryvyl shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 sales guidance.

BLMN

GDDY

Starboard Value's Q3 2024 13F Filing Shows Reduced Stakes In GoDaddy By 32% To 3.13M Shares, Salesforce By 14% To 1.44M Shares, Humana By 62% To 191K Shares, And Bloomin' Brands By 14%

Trading Ideas

AAPL

AMZN

Third Point 13F Shows Decreased Stake In PG&E Corp By 7% From 53,750,000 To 49,750,000 Shares; Amazon By 27% From 5,100,000 To 3,700,000 Shares; Danaher Corp By 5% From 2,050,000 To 1,950,000 Shares; Vistra Corp By 29% From 4,470,000 To 3,175,000 Shares; Microsoft By 45% From 1,580,000 To 870,000 Shares; Meta Platforms By 50% From 1,100,000  To 545,000 Shares; TSM By 12% From 2,025,000 To 1,780,000 Shares; Apple By 52% From 1,950,000 To 930,000 Shares; Amphenol Corp By 43% From 2,800,000 To 1,600,000 Shares

AISP

Airship AI shares are trading lower after the company reported worse-than-expected Q3 revenue results.

ADSK

MTCH

Starboard Value's Q3 2024 13F Filing Reveals New Stakes In Autodesk With 1.85M Shares, Match Group With 9.56M Shares

SEC Chairman Gary Gensler on Thursday defended his regulatory approach to crypto markets, emphasizing investor protection and compliance, as he hinted at an end of his stint as <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41883348/donald-trump-cant-fire-gary-gensler-but-pro-crypto-policies-means-industry-is-on-the-verge-of-a-golden-era">the agency&#8217;s chair</a>.
What Happened: In his remarks at the Practicing Law Institute&#8217;s 56th Annual Institute on Securities Regulation, Gensler <a href="https://www.sec.gov/newsroom/speeches-statements/gensler-remarks-pli-s-56th-annual-institute-securities-regulation-111424">noted</a> that his agenda builds on the SEC's history of oversight in crypto, referencing cases like Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), and emphasized the consistency of the Commission's actions over the years.
He said that since 2018, around 5-7% of SEC enforcement has been directed toward digital assets, maintaining that the agency&#8217;s approach targets specific non-compliant participants rather than the entire crypto market. 
He affirmed that "court after court" has upheld the SEC's jurisdiction over offerings that involve securities, even in digital forms.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41985685/investor-loses-25m-due-to-misplaced-crypto-transfer-says-cexs-feel-more-secure">Investor Loses $25M Due To Misplaced Crypto Transfer, Says CEXs Feel More Secure</a>
"Everything we've done is focused on ensuring compliance with our laws," Gensler said. 
He added that investor protection, through disclosure and oversight, has been a central priority, adding that compliance fosters market trust. 
Highlighting the SEC's endorsement of Bitcoin futures ETFs in 2021 and later Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) products, Gensler claimed these regulated products provided benefits such as lower fees and enhanced transparency, distinguishing them from the broader crypto markets.
His also noted that while Bitcoin, Ether, and stablecoins comprise a large portion of the crypto market, other assets—often speculative—had yet to demonstrate enduring use cases.
Gensler closed with thanking the team at the Securities and Exchange Commission, emphasizing it has been a &#8220;great honor to serve with them, doing the people's work and ensuring that our capital markets remain the best in the world.&#8221;
What&#8217;s Next: As Gensler&#8217;s term draws to a close, his approach remains influential. His remarks come as the digital asset community gathers insights at events like Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19, where regulatory and innovation discussions continue to unfold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41984505/bitcoin-to-peak-at-180000-says-vanecks-head-of-digital-assets-research">Bitcoin To Peak At $180,000, Says VanEck&#8217;s Head Of Digital Assets Research</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

Gary Gensler Hints At Ending His Stint As SEC Chair, Defends Crypto Regulation Agenda

ONCT

Oncternal Therapeutics Announced Workforce Reduction Effective December 2, 2024; Four Employees Will Remain In A Part-time Capacity In Connection With Exploration Of Strategic Alternatives; Expects $2.4M In Charges From Workforce Reduction

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) with a Buy and maintains $15 price target.

Price Target

Analyst Ratings

RVPH

D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $15 Price Target

Third Point 13F Shows Increased Stake In Intercontinental Exchange By 109% From 1,000,000 To 2,085,000 Shares; Live Nation Entertainment By 71% From 1,365,000 To 2,340,000 Shares; CRH By 215% From 650,000 To 2,050,000 Shares; Telephone & Data Systems By 27% From 2,266,060 To 2,875,000 Shares

Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.87) by 3.45 percent.

Kodiak Sciences Q3 2024 GAAP EPS $(0.84) Beats $(0.87) Estimate

Offerings

Associated Banc-Corp Announces Proposed Common Stock Offering Of 11.5M Shares

ANSS

FERG

LPLA

TSLA

Third Point 13F Shows Added Stake In Brookfield Corp With 4,725,000 Shares; Ferguson Enterprises With 965,000 Shares; Flutter Entertainment With 510,000 Shares; LPL Financial Holdings With 485,000 Shares; Carpenter Technology With 660,000 Shares; Tesla With 400,000 Shares; CVS Health Corp With 1,575,000 Shares; Ansys With 255,000 Shares; Hawaiian Electric Industries With 1,535,000 Shares; Clear Channel Outdoor Holdings With 850,000 Shares

ABVX

Abivax Q3 Total Principal Debt Outstanding €106.3M Down From €108.4M YoY

Events

ASTS

AST SpaceMobile Announced It Has Made Significant Strides Its Mission To Establish the First Space-Based Cellular Broadband Network

Calidi Biotherapeutics warrants delist from NYSE

Calidi (CLDI) Biotherapeutics will present data supporting RTNova, the company's systemic antitumor virotherapy platform, at the International Onco...

Calidi to present data supporting RTNova at upcoming conferences

Warning: CLDI is at high risk of performing badly

Calidi Biotherapeutics GAAP EPS of -$0.65

Calidi Biotherapeutics announces proposed offering

Calidi (CLDI) Biotherapeutics announced that it intends to offer to sell shares of its common stock in an public offering. All of the shares of com...

Calidi announces common stock offering, no amount given

Calidi Biotherapeutics announces pricing of $7.5M public offering of common stock

Calidi (CLDI) Biotherapeutics has priced its public offering of 4,437,869 shares of the Company's common stock at a price of $1.69 per share. The c...

Calidi prices 4.4M shares at $1.69 in public offering

CLDI

Screenshot 2024-03-05 at 6.31.45 PM

Biotech

CADL

CGON

TOVX

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Press Releases

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

Financing

Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement

Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Proposed Public Offering

IPOs

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

BOXL

GRRR

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Clene

CEL-SCI

Elevation Oncology

Fortress Biotech

FibroGen

HOOKIPA Pharma

Immix Biopharma

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kala Bio

Lantern Pharma

Lumos Pharma

NextCure

OKYO Pharma

Passage Bio

Pluri

Rallybio

Serina Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

X4 Pharmaceuticals

Xilio Therapeutics

Ladenburg Thalmann

Baird

HC Wainwright & Co.

Calidi Biotherapeutics shares are trading lower after the company announced the pricing of its $7.5 million public offering of 4,437,869 shares at a price of $1.69 per share.

Comments

Calidi Biotherapeutics

뉴스

에 대한 최신 뉴스 Calidi Biotherapeutics (AMEX:CLDI) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌